Previous studies on CML biomarkers primarily focused on BCR-ABL transcript levels or somatic mutations (1), which lack specificity in distinguishing CML from other hematologic malignancies (e.g., AML with monocytic differentiation or MDS with fibrosis). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.